n = 1517 | |
---|---|
Age, yrs | 55.1 ± 11.7 |
Female | 1340 (88.3) |
White | 1358 (89.5) |
Hispanic | 75 (4.9) |
Rurala | 214/1454 (14.1) |
Autoimmune conditions | |
RA | 925 (61.0) |
PsA | 299 (19.7) |
AS | 185 (12.2) |
SLE | 108 (7.1) |
Medications | |
bDMARD | 790 (52.1) |
JAK inhibitor | 158 (10.4) |
Methotrexate | 946 (62.4) |
Hydroxychloroquine | 537 (35.4) |
Glucocorticoids | 402 (26.5) |
NSAID | 373 (24.6) |
Comorbidities | |
Hypertension | 621 (40.9) |
Lung disease | 518 (34.2) |
DM | 179 (11.8) |
Heart disease | 121 (8.0) |
Kidney disease | 80 (5.3) |
Malignancy | 33 (2.2) |
Current smoking | 141 (9.3) |
PROMIS Anxiety, T-scoreb | 59.8 ± 8.5 |
Values are n (%) or mean ± SD.
↵aRural status shown among participants with available zip code.
↵bPROMIS Anxiety short form with range of 1-100, US adult population (mean 50 ± SD 10). AS: ankylosing spondylitis; bDMARD: biologic disease-modifying antirheumatic drug; DM: diabetes mellitus; JAK: Janus kinase; NSAID: nonsteroidal antiinflammatory drug; PsA: psoriatic arthritis; PROMIS: Patient-Reported Outcomes Measurement Information System; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus.